300765 石药创新
已收盘 07-16 15:00:00
资讯
新帖
简况
石药创新(300765.SZ)控股子公司SYS6043启动Ⅲ期临床试验
智通财经 · 16:59
石药创新(300765.SZ)控股子公司SYS6043启动Ⅲ期临床试验
7月15日石药创新涨12.33%，工银前沿医疗股票A基金重仓该股
证券之星 · 07-15 16:36
7月15日石药创新涨12.33%，工银前沿医疗股票A基金重仓该股
7月9日石药创新涨7.47%，工银前沿医疗股票A基金重仓该股
证券之星 · 07-09
7月9日石药创新涨7.47%，工银前沿医疗股票A基金重仓该股
石药创新（300765）披露2026年第三次临时股东会决议公告，7月8日股价下跌0.91%
证券之星 · 07-08
石药创新（300765）披露2026年第三次临时股东会决议公告，7月8日股价下跌0.91%
7月3日石药创新涨6.44%，工银前沿医疗股票A基金重仓该股
证券之星 · 07-03
7月3日石药创新涨6.44%，工银前沿医疗股票A基金重仓该股
石药创新（300765）披露股票交易异常波动公告，7月2日股价上涨12.16%
证券之星 · 07-02
石药创新（300765）披露股票交易异常波动公告，7月2日股价上涨12.16%
7月2日石药创新（300765）龙虎榜数据：机构净买入4607.42万元（3日），北向资金净卖出3405.27万元（3日）
证券之星 · 07-02
7月2日石药创新（300765）龙虎榜数据：机构净买入4607.42万元（3日），北向资金净卖出3405.27万元（3日）
石药创新(300765.SZ)：注射用SYS6043被纳入突破性治疗品种名单
智通财经 · 07-02
石药创新(300765.SZ)：注射用SYS6043被纳入突破性治疗品种名单
石药创新宣布子公司与阿斯利康达成合作、期权及许可协议
美股速递 · 07-02
石药创新宣布子公司与阿斯利康达成合作、期权及许可协议
石药创新(300765.SZ)子公司巨石生物与阿斯利康达成新型肝外递送小干扰核酸创新药物战略合作
智通财经 · 07-02
石药创新(300765.SZ)子公司巨石生物与阿斯利康达成新型肝外递送小干扰核酸创新药物战略合作
7月1日石药创新涨12.93%，工银前沿医疗股票A基金重仓该股
证券之星 · 07-01
7月1日石药创新涨12.93%，工银前沿医疗股票A基金重仓该股
石药创新：控股子公司SYS6010启动Ⅲ期临床试验
格隆汇 · 06-30
石药创新：控股子公司SYS6010启动Ⅲ期临床试验
6月29日石药创新涨9.06%，工银前沿医疗股票A基金重仓该股
证券之星 · 06-29
6月29日石药创新涨9.06%，工银前沿医疗股票A基金重仓该股
石药创新最新公告：控股子公司SYS6010启动Ⅲ期临床试验
证券之星 · 06-26
石药创新最新公告：控股子公司SYS6010启动Ⅲ期临床试验
6月24日石药创新涨5.86%，工银前沿医疗股票A基金重仓该股
证券之星 · 06-24
6月24日石药创新涨5.86%，工银前沿医疗股票A基金重仓该股
“再战”港交所：石药集团附属公司石药创新递交最新上市申请
财中社 · 06-22
“再战”港交所：石药集团附属公司石药创新递交最新上市申请
石药集团：拟分拆石药创新H股上市
南方财经网 · 06-22
石药集团：拟分拆石药创新H股上市
【新股IPO】石药创新(300765)向港交所主板提交上市申请 拟实现“A+H”上市
金吾财讯 · 06-22
【新股IPO】石药创新(300765)向港交所主板提交上市申请 拟实现“A+H”上市
每周股票复盘：石药创新（300765）拟更名并推进多项新药研发
证券之星 · 06-21
每周股票复盘：石药创新（300765）拟更名并推进多项新药研发
新股消息 | 石药创新(300765.SZ)二次递表港交所
智通财经 · 06-20
新股消息 | 石药创新(300765.SZ)二次递表港交所
暂无数据
公司概况
公司名称：
石药创新制药股份有限公司
所属行业：
食品制造业
上市日期：
2019-03-22
主营业务：
石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是恩朗苏拜单抗注射液、注射用奥马珠单抗注射液、咖啡因、阿卡波糖、果维康维生素C咀嚼片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一，已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。
发行价格：
24.47
{"stockData":{"symbol":"300765","market":"SZ","secType":"STK","nameCN":"石药创新","latestPrice":39.97,"timestamp":1784185437000,"preClose":42,"halted":0,"volume":26190427,"delay":0,"changeRate":-0.0483,"floatShares":1405000000,"shares":1405000000,"eps":-0.2194,"marketStatus":"已收盘","change":-2.03,"latestTime":"07-16 15:00:00","open":40.08,"high":42.77,"low":39,"amount":1064000000,"amplitude":0.0898,"askPrice":40,"askSize":1354,"bidPrice":39.97,"bidSize":380,"shortable":0,"etf":0,"ttmEps":-0.2194,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784251800000},"marketStatusCode":5,"adr":0,"adjPreClose":42,"symbolType":"stock","openAndCloseTimeList":[[1784165400000,1784172600000],[1784178000000,1784185200000]],"highLimit":46.2,"lowLimit":37.8,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1404592944,"isCdr":false,"pbRate":22.89,"roa":"--","roe":"--","epsLYR":-0.1731,"committee":0.069399,"marketValue":56142000000,"turnoverRate":0.0186,"status":1,"floatMarketCap":56142000000},"requestUrl":"/m/hq/s/300765/tweets","defaultTab":"tweets","newsList":[{"id":"2651141082","title":"石药创新(300765.SZ)控股子公司SYS6043启动Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2651141082","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651141082?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:59","pubTimestamp":1784192382,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药创新 发布公告，公司控股子公司石药集团巨石生物制药有限公司已于近日启动一项评价SYS6043对比研究者选择的化疗用于铂耐药晚期卵巢癌、原发性腹膜癌以及输卵管癌参与者的随机、多中心、开放标签的Ⅲ期临床试验。与传统野生型可结芯片段不同，SYS6043可减少淋巴细胞摄取，降低脱靶毒性风险，从而提高治疗安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","300765","BMED","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651455865","title":"7月15日石药创新涨12.33%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651455865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651455865?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:36","pubTimestamp":1784104562,"startTime":"0","endTime":"0","summary":"证券之星消息，7月15日石药创新涨12.33%创60日新高，收盘报42.0元，换手率2.42%，成交量33.99万手，成交额13.99亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共43家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500031207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650420739","title":"7月9日石药创新涨7.47%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650420739","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650420739?lang=zh_cn&edition=full","pubTime":"2026-07-09 16:30","pubTimestamp":1783585858,"startTime":"0","endTime":"0","summary":"证券之星消息，7月9日石药创新涨7.47%，收盘报36.38元，换手率1.93%，成交量27.11万手，成交额9.66亿元。重仓石药创新的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共43家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900028694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649991224","title":"石药创新（300765）披露2026年第三次临时股东会决议公告，7月8日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649991224","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649991224?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:10","pubTimestamp":1783519827,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，石药创新报收于33.85元，较前一交易日下跌0.91%，最新总市值为475.45亿元。石药创新制药股份有限公司于2026年7月8日召开2026年第三次临时股东会，会议由董事会召集，董事长姚兵主持，现场会议在河北省石家庄市高新区中山东路896号公司会议室举行。通过现场和网络投票的股东共328人，代表股份1,182,283,308股，占公司有表决权股份总数的84.8980%。中小股东对该议案的同意比例为99.8259%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800042571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648524816","title":"7月3日石药创新涨6.44%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648524816","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648524816?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:46","pubTimestamp":1783068386,"startTime":"0","endTime":"0","summary":"证券之星消息，7月3日石药创新涨6.44%创60日新高，收盘报36.71元，换手率2.86%，成交量40.13万手，成交额14.18亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共43家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300030288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648685940","title":"石药创新（300765）披露股票交易异常波动公告，7月2日股价上涨12.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648685940","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648685940?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:22","pubTimestamp":1783002139,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，石药创新报收于34.49元，较前一交易日上涨12.16%，最新总市值为484.44亿元。该股当日开盘30.9元，最高34.66元，最低30.8元，成交额达13.06亿元，换手率为2.79%。公司于近日披露《关于股票交易异常波动公告》，称其股票交易连续三个交易日收盘价格涨幅偏离值累计超过30%，构成股票交易异常波动。公司及控股股东不存在应披露而未披露的重大事项，股票异常波动期间控股股东未买卖公司股票。公司将于2026年8月21日披露2026年半年度报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200042058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648506816","title":"7月2日石药创新（300765）龙虎榜数据：机构净买入4607.42万元（3日），北向资金净卖出3405.27万元（3日）","url":"https://stock-news.laohu8.com/highlight/detail?id=2648506816","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648506816?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:42","pubTimestamp":1782985338,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年7月2日公布的交易公开信息显示，石药创新因连续三个交易日内，涨幅偏离值累计达到30%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年7月2日收盘，石药创新报收于34.49元，上涨12.16%，换手率2.79%，成交量39.13万手，成交额13.06亿元。从龙虎榜公布的三日买卖数据来看，机构合计净买入4607.42万元，北向资金合计净卖出3405.27万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200029807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648650393","title":"石药创新(300765.SZ)：注射用SYS6043被纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2648650393","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648650393?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:00","pubTimestamp":1782982807,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药创新 发布公告，公司的控股子公司石药集团巨石生物制药有限公司开发的注射用SYS6043被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。目前，公司已正式启动SYS6043针对上述适应症的Ⅲ期确证性临床试验，全力推进研发上市进程。与此同时，SYS6043用于小细胞肺癌一线、二线治疗及乳腺癌等多个实体瘤的临床试验正在同步开展，多瘤种研发布局稳步推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药创新(300765.SZ)：注射用SYS6043被纳入突破性治疗品种名单","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161856978","title":"石药创新宣布子公司与阿斯利康达成合作、期权及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1161856978","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161856978?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:59","pubTimestamp":1782982756,"startTime":"0","endTime":"0","summary":"石药创新制药公司宣布，其子公司已与阿斯利康签署了一项合作、期权及许可协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648503310","title":"石药创新(300765.SZ)子公司巨石生物与阿斯利康达成新型肝外递送小干扰核酸创新药物战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2648503310","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648503310?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:53","pubTimestamp":1782982410,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药创新 发布公告，公司的控股子公司石药集团巨石生物制药有限公司与阿斯利康于2026年7月1日签署《合作、选择权及授权协议》，将与阿斯利康在新型小干扰核酸候选药物领域开展战略合作，开发新型肝外递送小干扰分子核酸候选药物。阿斯利康将向巨石生物支付首付款3,000万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","LU2237443622.USD","LU2456880835.USD","LU0708994859.HKD","LU2236285917.USD","LU0109394709.USD","LU2462157665.USD","LU1267930573.SGD","LU2468319806.SGD","LU2417539215.USD","LU2089984988.USD","BK0226","LU0889565916.HKD","LU0432979614.USD","AZN","LU0058720904.USD","LU0310800379.SGD","BK4568","LU2237443978.SGD","BK4007","159992","BK4585","BK4588","LU2237443382.USD","BK1161","LU0128525929.USD","LU2237443465.HKD","LU2237443549.SGD","BK1574","AZNH","IE00B3T34201.USD","LU0320765992.SGD","LU1829250122.USD","300765","LU0289739699.SGD","LU0029864427.USD","LU2237443895.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648516148","title":"7月1日石药创新涨12.93%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648516148","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648516148?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:54","pubTimestamp":1782896063,"startTime":"0","endTime":"0","summary":"证券之星消息，7月1日石药创新涨12.93%，收盘报30.75元，换手率1.88%，成交量26.4万手，成交额7.69亿元。重仓石药创新的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共43家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647718536","title":"石药创新：控股子公司SYS6010启动Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2647718536","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647718536?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:57","pubTimestamp":1782809868,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647322907","title":"6月29日石药创新涨9.06%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322907","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647322907?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:52","pubTimestamp":1782723163,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日石药创新涨9.06%，收盘报27.7元，换手率1.58%，成交量22.2万手，成交额6.0亿元。重仓石药创新的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共43家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","159891","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646355057","title":"石药创新最新公告：控股子公司SYS6010启动Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2646355057","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646355057?lang=zh_cn&edition=full","pubTime":"2026-06-26 17:57","pubTimestamp":1782467859,"startTime":"0","endTime":"0","summary":"石药创新(300765.SZ)公告称，公司控股子公司巨石生物已启动SYS6010联合恩朗苏拜单抗一线治疗驱动基因阴性PD-L1阳性的局部晚期或转移性非小细胞肺癌的Ⅲ期临床试验。该药物为靶向EGFR的抗体偶联药物，已获国家药监局同意开展临床试验。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600033714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645895472","title":"6月24日石药创新涨5.86%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645895472","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645895472?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:48","pubTimestamp":1782290913,"startTime":"0","endTime":"0","summary":"证券之星消息，6月24日石药创新涨5.86%，收盘报26.03元，换手率1.75%，成交量24.52万手，成交额6.41亿元。重仓石药创新的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共43家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400030327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","159891","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645400320","title":"“再战”港交所：石药集团附属公司石药创新递交最新上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2645400320","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645400320?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:54","pubTimestamp":1782118440,"startTime":"0","endTime":"0","summary":"6月22日，石药集团（01093）发布公告，董事会宣布，石药创新于其先前的上市申请失效后，已于2026年6月18日向联交所提交其最新上市申请。石药创新完成上市后，将仍为公司的间接附属公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606223778073222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1008478684.HKD","LU1226288253.USD","LU0501845795.SGD","LU1226287792.SGD","LU1960683339.HKD","LU2039709279.SGD","LU1226288170.HKD","IE0008369823.USD","LU1951186391.HKD","LU0315179316.USD","IE00BZ08YR35.GBP","IE0008368742.USD","LU1813983027.USD","LU1226287529.USD","01093","LU0140636845.USD","LU1226287875.USD","LU0072913022.USD","SG9999004220.SGD","IE00B031HY20.USD","LU1328277881.USD","BK1515","300765","LU1152091168.USD","BK1521","LU0067412154.USD","LU1807302812.USD","LU0880133367.SGD","IE00BZ08YS42.EUR","LU0314109678.HKD","BK1191","HK0000165453.HKD","IE00BZ08YT58.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","IPOS","LU1152091754.HKD","LU0326950275.SGD","LU1993786604.SGD","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645104008","title":"石药集团：拟分拆石药创新H股上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2645104008","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645104008?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:49","pubTimestamp":1782118140,"startTime":"0","endTime":"0","summary":"南财智讯6月22日电，石药集团（01093.HK）发布须予披露交易公告，公司间接附属公司石药创新制药股份有限公司已于2026年6月18日就H股建议上市向联交所提交最新上市申请。本次分拆上市完成后，石药创新仍将为公司间接附属公司。H股建议上市尚需取得中国证监会、联交所及香港证监会等相关监管机构的备案和/或批准，具体时间表、发售规模及架构尚未最终确定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606223778067894.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1951186391.HKD","LU1008478684.HKD","BK0226","01093","LU0314109678.HKD","LU1226287875.USD","IPOS","LU0326950275.SGD","LU1807302812.USD","LU1960683339.HKD","LU1993786604.SGD","IE0008368742.USD","IE00B031HY20.USD","LU0501845795.SGD","LU1328277881.USD","IE00BZ08YR35.GBP","HK0000165453.HKD","300765","LU1226287529.USD","LU0140636845.USD","LU1226288253.USD","IE00B543WZ88.USD","LU1813983027.USD","BK1191","IE00BZ08YT58.USD","LU1152091168.USD","LU0880133367.SGD","LU0072913022.USD","BK1515","LU0315179316.USD","LU2039709279.SGD","LU1226288170.HKD","SG9999004220.SGD","IE0008369823.USD","BK1521","LU0067412154.USD","IE00BZ08YS42.EUR","LU1152091754.HKD","IE00B5MMRT66.SGD","LU1226287792.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645014426","title":"【新股IPO】石药创新(300765)向港交所主板提交上市申请 拟实现“A+H”上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2645014426","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645014426?lang=zh_cn&edition=full","pubTime":"2026-06-22 08:53","pubTimestamp":1782089634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所6月18日披露，石药创新 向港交所主板提交上市申请，拟实现“A+H”上市，中信证券为其独家保荐人。公司于2023年至2025年分别录得收入25.39亿元、19.81亿元以及21.58亿元，同期对应年内利润1.26亿元，亏损3.04亿元以及亏损6.34亿元。公司2023年至2025年的研发费用分别为6.71亿元、8.43亿元以及10.61亿元。股东方面，恩必普药业、石药欧意药业、康日、佳曦及石药集团构成一组控股股东集团。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/Nzc3MzgwMzMzMzM4NGQyNThhOGYxYzk1ZjFmM2VmN2U1NDI1NjgyMzc0Ng==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Nzc3MzgwMzMzMzM4NGQyNThhOGYxYzk1ZjFmM2VmN2U1NDI1NjgyMzc0Ng==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984132","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0226","IPOS","HEXmain","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645272095","title":"每周股票复盘：石药创新（300765）拟更名并推进多项新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2645272095","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645272095?lang=zh_cn&edition=full","pubTime":"2026-06-21 02:14","pubTimestamp":1781979252,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，石药创新报收于23.95元，较上周的23.23元上涨3.1%。本周，石药创新6月17日盘中最高价报26.21元。第七届董事会第二次会议决议公告石药创新制药股份有限公司于2026年6月16日召开第七届董事会第二次会议，审议通过《关于变更证券简称的议案》。董事会同意将证券简称由“新诺威”变更为“石药创新”。截至公告日，公司使用闲置募集资金进行现金管理尚未到期金额为3.4亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100000561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644619330","title":"新股消息 | 石药创新(300765.SZ)二次递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2644619330","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644619330?lang=zh_cn&edition=full","pubTime":"2026-06-20 07:48","pubTimestamp":1781912933,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所6月18日披露，石药创新制药股份有限公司(简称：石药创新(300765.SZ))递表港交所主板，中信证券为其独家保荐人。该公司曾于2025年12月10日向港交所递交上市申请。招股书显示，根据弗若斯特沙利文资料，自2020年至2025年，按收入和出货量计，石药创新始终保持着全球最大化学合成咖啡因生产商地位，公司主要生产用作功能性饮料中的食品添加剂的咖啡因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK0226","300765","HEXmain"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784213011069,"stockEarnings":[{"period":"1week","weight":0.2408},{"period":"1month","weight":0.808},{"period":"3month","weight":0.2353},{"period":"6month","weight":0.05},{"period":"1year","weight":-0.2267},{"period":"ytd","weight":0.1644}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":-0.0345},{"period":"3month","weight":-0.0246},{"period":"6month","weight":-0.0357},{"period":"1year","weight":0.1286},{"period":"ytd","weight":-0.0033}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石药创新制药股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"23758人(较上一季度增加4.55%)","perCapita":"59120股","listingDate":"2019-03-22","address":"河北省石家庄市栾城区张举路62号","registeredCapital":"140459万元","survey":" 石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是恩朗苏拜单抗注射液、注射用奥马珠单抗注射液、咖啡因、阿卡波糖、果维康维生素C咀嚼片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一，已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。","listedPrice":24.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药创新(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药创新,300765,石药创新股票,石药创新股票老虎,石药创新股票老虎国际,石药创新行情,石药创新股票行情,石药创新股价,石药创新股市,石药创新股票价格,石药创新股票交易,石药创新股票购买,石药创新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药创新(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}